

National Institute for Health & Clinical Excellence**Neuropathic Pain****Guideline Development Group (GDG) meeting 4**29th & 30th January 2013

Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BD

GROUP MEMBERSHIP

In Attendance	
GDG Members	
Damien Longson (DL) (Chair)	Vera Neumann (VN)
Brigitta Brandner (BB)	Paul Howard (PH)
Annette Gibb (AG)	Heather Wallace (HW)
Sam Chong (SC)	Sailesh Sankar (SS)
Issak Bhojani (IB)	
Ammy Pui-Chi Lam (AP)	
Karen Cavanagh (KC)	
NICE Staff	
Stephanie Mills (SM)	Jasdeep Hayre (JH)
Heather Stegenga (HS)	James Mahon (MH)
Clifford Middleton (CM)	
Gabriel Rogers (GR)	
Sarah Glover (SG)	
Michael Heath (MH)	
Nicole Elliott (NE)	
Apologies:	
Marie Fallon (MF)	Clifford Middleton (30 th Jan 2013 only)
Nicole Elliott (30 th Jan 2013 only)	
James Mahon (30 th Jan 2013 only)	

MINUTES OF THE MEETINGWed 29th January 2013**1.1 Agenda item 1: Introductions & guideline development group (GDG) working**

DL welcomed all GDG members. The group checked the minutes of the third meeting, which were agreed with no amendments to be made. Each person was asked to declare any conflicts of interest over and above what had been declared since the last meeting. There were no declarations to add from any members. DL stated that the main objectives of the meeting would be to look at the challenges of the evidence base for neuropathic pain so far, be updated on the health economic model development and look at some of the evidence for peripheral neuropathic pain.

2 Agenda item 2: Update on progress and approach to presenting the evidence

MH explained to the group that the NICE commissioning team had allowed some extra time in the development of the guideline to enable the GDG to have enough time to consider the clinical evidence. The GDG indicated that this extra time would be important to ensure production of a good quality guideline.

HS explained the approaches to the clinical evidence including reporting of critical and important outcomes and recapped that at the previous meeting the GDG had agreed how to categorise the evidence. HS went through some of the difficulties in splitting the evidence in certain ways and the GDG discussed this.

2.1 Agenda item 3: Review of principles of best practice

The group looked at the best practice recommendations which were made as part of the previous neuropathic pain guideline. These principles contextualised the recommendations made on pharmacological management of neuropathic pain.

2.2 Agenda item 4: Health economics

Prior to the health economic presentation from JM, HS spoke briefly about the evidence for peripheral pain to be presented on day 2 of the meeting.

JM showed the group the work that had been done on the development of the health economic model so far. The group discussed the costs that had been found for the drugs within the clinical evidence for peripheral pain.

2.3 Agenda item 5: Summary of the day

DL thanked the group for their input on day 1. The GDG were given all the evidence to be presented on day 2 for peripheral pain and asked to look at this ahead of the second day.

Thursday 30th January 2013

2.4 Agenda item 1: Review of day 1

DL summarised day 1 of the meeting and talked to the group about presentation of the evidence, clinical discussion, evidence statements and decision-making.

GR talked to the group briefly about the health economics and assured the group that more would be presented on this at the next meeting.

2.5 Agenda item 2 & 3: Review of included evidence

HS began by briefly explaining how the included studies were quality assessed and talking a little more about the analysis. HS took the group through the

results, including the probability ranks and rankograms which had been produced. HS discussed with the GDG the possibility of combining similar adverse events which had sometimes been reported separately in the literature.

2.6 Agenda item 4: Review of best practice principles

This was moved forward and discussed on day 1.

2.7 Agenda item 5: Summary of the day and next steps to the March meeting

DL and SM thanked the group for their contributions. The GDG were informed that the additional meeting scheduled for the 19th & 20th March 2013 in Manchester may change and that the GDG would be updated on this as soon as possible. SM told the group about the new dates for guideline consultation. SM confirmed that the evidence tables, GRADE and results tables and excluded study lists would be distributed.